The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.

Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.

The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...

US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial.

Good morning, let’s get straight into the news today. Pfizer said this morning that its drug Ibrance showed efficacy in a ...

Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...